Patient-centric data analytics to simulate clinical development and improve decision making

Powered by the world’s largest clinical trials database, Phesi’s AI-driven solutions enable life sciences companies to accelerate drug development and commercialization. Turn real world clinical trial data into insights and answers with our Trial Accelerator™ platform generating Digital Patient Profiles, Digital Twins and Digital Trial Arms.

Smarter trials, faster cures. Delivered.

Request a demo to access the data for your indication
The Phesi Advantage

Data-driven clinical development

Patient-centric data analytic solutions, trusted by the world’s leading pharmaceutical companies.

Optimizing program and protocol design by creating Digital Patient Profiles, Digital Twins and Digital Trial Arms, we can help you improve patient population accuracy and diversity, reduce trial timelines and patient burden, across every stage of clinical development for any indication, including rare diseases. 

The power behind every successful trial.

Read more

World’s largest clinical trials database

Trial Accelerator Platform enables predictive modelling in 4 key views: Patient Profile, Trial Performance, Country, Investigator Site

Digital Twin and Digital Trial Arm services generate reliable evidence without the expense or time needed in traditional trials

Powered by the Phesi proprietary integrated methodology and cutting edge AI technologies

485 k

Curated clinical trials

4.2 m


90 k

Updated data sources

60 m+


4000 +

Disease indications

our clients

Customer experience

Phesi is on the frontiers of defining clinical development as a science, performing systematic analysis of the clinical trial, clinical protocol, and clinical site space to form hypotheses about what will work and what will not. Through observation and experiment you are applying those learnings to inform new clinical programs or save old ones. Phesi is more than the sum of its parts and the value is in the integration.


Every global R&D leader should know about this and should be testing it within their portfolio.

senior director, clinical operations Takeda

Phesi worked with us to show that a particular adaptive trial design would give the best performance. The result was a significantly quicker and cheaper devel­opment time on this priority asset.

senior director, clinical operations Takeda
News & events
01. 16. 2023
New Phesi global analysis sees breast cancer retain position as most studied disease area in 2022 Read more
11. 30. 2022
Number of collagen clinical trials more than doubled since 2010, Phesi analysis shows Read more
10. 14. 2022
Phesi launches AI-driven Trial Accelerator™ to enable simulated trials and deliver comprehensive view of the patient throughout clinical development and commercialization Read more
10. 06. 2022
Almost half of Ukraine’s clinical trials to find new therapies are still recruiting patients despite ongoing conflict, Phesi analysis shows Read more
09. 21. 2022
New Phesi Analysis of 117,000 Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants Read more
06. 23. 2022
48% of US cancer clinical trials have no Hispanic or Latin American representation, and 42% do not include a single Black patient, Phesi analysis reveals Read more